What are the indications for erdafitinib? Which cancer patients is it suitable for?

Erdafitinib is a targeted drug mainly used to treat cancer patients with FGFR mutations. It inhibits the growth of tumor cells by targeting and inhibiting the fibroblast growth factor receptor (FGFR) signaling pathway. Erdafitinib is approved to treat certain types of urothelial cancer (cancer of the urinary tract), especially in patients whose tumors have progressed despite chemotherapy. Clinical studies have shown that erdafitinib has a significant therapeutic effect on these patients, delaying the progression of the disease and improving quality of life.

In addition to urinary tract cancer, erdafitinib is also suitable for patients with other solid tumors with FGFR gene mutations. Research shows that FGFR gene mutations appear in a variety of malignant tumors, including gastric cancer, non-small cell lung cancer, etc. Although clinical studies for these indications are ongoing, erdafitinib has shown potential in the treatment of tumors targeting FGFR mutations.

Erdafitinib is usually suitable for patients with advanced or metastatic cancer whose genetic testing shows the presence of FGFR gene mutations. For these patients, erdafitinib, as a targeted therapy, can effectively inhibit tumor growth, providing patients with new treatment options, especially when traditional treatments are ineffective or there are no other treatment options.

However, erdafitinib is not a treatment option for all cancer patients. Good efficacy with erdafitinib is only possible in patients with specific FGFR mutations. Therefore, patients need genetic testing to make sure the right type of mutation is present in their cancer before starting treatment. This type of personalized treatment can help improve treatment effectiveness and reduce the occurrence of side effects.

Reference link:https://www.balversa.com/